Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Benedito Arruda CarneiroKyriakos P PapadopoulosJohn H StricklerAndrew B LassmanSaiama N WaqarYoung Kwang ChaeJyoti D PatelEinat Shacham-ShmueliKaren KellyMustafa KhasrawChristine M BestvinaRyan MerrellKevin HuangHarisha AtluriPeter AnsellRachel LiJanet JinMark G AndersonEdward B ReillyGladys Morrison-ThieleKalpesh PatelRandy R RobinsonMartha R Neagu AristideHui K GanPublished in: Neuro-oncology advances (2022)
Ser-T monotherapy at doses up to 50 μg/kg initial dose, followed by 25 μg/kg Q4W demonstrated a tolerable safety profile with minimal antitumor activity observed in patients with glioblastoma. The glioblastoma dose-expansion cohort was closed due to a lack of efficacy (NCT03234712).